Category: clinical study retractions

“Exactly the same clinical study” published six times

4A group of researchers conducted a clinical trial on hundreds of hypertensive patients. Then, they published the results…six times.

The “nearly identical” papers came to our attention via a retraction in Inflammation. Editor in chief Bruce Cronstein explained how he learned of the mass duplication:

The editors were contacted en masse by somebody doing a Cochrane Review on hypertension and who noticed that the content of the 6 papers was nearly identical.  Frankly, not one of us would have noticed otherwise.

Another of those papers, in the European Journal of Pharmaceutical Sciences, has also been retracted. That note is similar to the retraction notice for the Inflammation paper, both of which have been cited twice:

Continue reading “Exactly the same clinical study” published six times

Running shoe paper pulled for failing to disclose author’s industry ties

87507315-105.4.coverNot so fast — a paper that showed wearing Vibram FiveFingers (resembling foot gloves) “may help reduce running-related injuries” has been removed after the editors realized the first author is on Vibram’s advisory board.

Managing editor Noelle A. Boughanmi told us there’s no retraction here — the journal is just fixing the paper to address the relationship of podiatrist Nick Campitelli with the company featured in the article.

There is still a copy of the paper on PubMed, which suggests these “minimalist shoes” strengthen key muscles.

The paper was published online by the Journal of the American Podiatric Medical Association. It was removed after editors realized that “the author did not fully disclose some involvement with the company,” Boughanmi said:

Continue reading Running shoe paper pulled for failing to disclose author’s industry ties

Three more retractions for former record-holder Boldt, maybe more to come

m_cover

Justus Liebig University in Germany has been investigating concerns that Joachim Boldt, number two on the Retraction Watch Leaderboard and now up to 92 retractions, may have “manipulated” more data than previously believed.

Until now, the vast majority of Boldt’s retractions were thought to have involved inadequate ethics approval. However, new retraction notices for Boldt’s research suggest that there’s evidence the researcher also engaged in significant data manipulation.

The first retraction from the university investigation emerged last year. Two of three new notices cite the investigation specifically, and an informant at the university told us that there are more retractions to come.

Here are the retracted papers that are freshly on the record, starting with an August retraction for a 1991 Anesthesiology paper (cited 37 times, according to Thomson Scientific’s Web of Knowledge):

Continue reading Three more retractions for former record-holder Boldt, maybe more to come

BMC editors update retraction after investigation clears authors of faking peer reviews

bmc-logo

Editors at BioMed Central have taken the unusual step of updating a retraction notice after an investigation found the authors were not responsible for a peer review process gone awry. The paper is one of  dozens of other papers retracted in March for fake peer reviews.

That month, the paper “Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia” in Diagnostic Pathology was among the 43 papers retracted due to fake peer reviews. (Retractions for the phenomenon — more about it in our Nature feature here — are up to about 170.)

According to the update posted in July, an investigation into the paper by the Jiading Central Hospital in Shanghai, where the authors work, found that they “did not participate in influencing the peer review process.”

Here’s more from the update to the notice:

Continue reading BMC editors update retraction after investigation clears authors of faking peer reviews

Drugmaker accused of omitting side effect data from 2003 Risperdal paper

cover7607A 2003 paper may have left out potentially “significant” data on the long-term side-effects of an antipsychotic drug used in children, according to a former head of the U.S. Food and Drug Administration.

As reported by the Toronto Star, David Kessler is alleging that Janssen, the maker of Risperdal (and owned by Johnson & Johnson), omitted data about the risks of the drug: In particular, that boys who use it over a long period may be at risk of growing breasts.

There’s anecdotal evidence of the side effect. One family claimed the drug had caused their son to grow a pair of 46 DD-sized breasts in a lawsuit against Johnson & Johnson, reported the Wall Street Journal in February. They won, to the tune of $2.5 million. The suit is apparently just one of 1,200 like it.

The abstract of the paper, “Prolactin levels during long-term risperidone treatment in children and adolescents,” published in The Journal of Clinical Psychiatry, suggests that levels of a key hormone aren’t a problem in the long term:

Continue reading Drugmaker accused of omitting side effect data from 2003 Risperdal paper

Authors withdraw immunology study, no reasons given

Journal of Biological Chemistry1Researchers have withdrawn a 2010 article in the Journal of Biological Chemistry about an immune regulator.

The paper was pulled without any explanation (in standard JBC style). Here’s the complete notice:

This article has been withdrawn by the authors.

The study’s authors were based out of Shandong University Medical School, Jinan General Hospital of Jinan Command and Duke University Medical Center.

Two of the authors have had previous papers retracted.

Continue reading Authors withdraw immunology study, no reasons given

The worm has turned: Nematode study retracted for misidentification

toxicol patholThe authors of a paper on parasitic nematodes have retracted the article because they misidentified the organism in question, so “the possibility of misleading readers was high.”

The paper, “Histopathological features of Capillaria hepatica infection in laboratory rabbits,” appeared in Toxicologic Pathology in 2009 and came from a lab at Huntingdon Life Sciences, in Cambridgeshire, England.

According to the abstract: Continue reading The worm has turned: Nematode study retracted for misidentification

Canadian researchers in legal battle over investigation object to third retraction

The Journal of Clinical InvestigationA third retraction — and a notice of concern — have emerged from the investigation into a husband and wife research team at the University of Toronto that found evidence of faked images and duplicated data.

The problem, according to the latest retraction note for Sylvia Asa and Shereen Ezzat, in the Journal of Clinical Investigation: Portions of the RT-PCR gels “are duplicated in this publication and in a subsequent publication.” That subsequent publication is a 2003 paper that has received a Notice of Concern from the American Journal of Pathology.

According to the retraction note, co-author Gillian E. Wu of York University signed off on the journal’s decision, but Asa, Ezzat and second author Lei Zheng dissented to the retraction. Third author Xian-Feng Zhu couldn’t be reached. Although corresponding author Asa noted that “the initial screen of these samples support the conclusions made in the paper,” the JCI made its position perfectly clear in the note:

Continue reading Canadian researchers in legal battle over investigation object to third retraction

Plague or anthrax on the subway? Think again, says now-corrected study

Cell SystemsAuthors of a widely covered study that documented traces of plague and anthrax on surfaces across New York City have revised the paper after public health officials challenged their interpretations of the data.

It’s hard to overestimate the attention these findings received when first published.

“Bubonic plague found in NYC subway,” wrote The Daily Beast.

“Your subway seat mate: Bubonic plague, anthrax, & mysterious DNA,” said Yahoo!

“NY subway has bubonic plague,” declared Newser.

Not so fast. In an erratum published July 29, the authors write: Continue reading Plague or anthrax on the subway? Think again, says now-corrected study

Nutrition researcher Chandra loses libel case against CBC

CBCThe self-proclaimed “father of nutritional immunology,” Ranjit Kumar Chandra, has lost a libel lawsuit against the Canadian Broadcasting Company (CBC).

The suit was in response to a 2006 three-part documentary from the CBC, which examined allegations of fraud against the former Memorial University researcher.

After the 58-day trial, the Ontario Superior Court of Justice “ruled in favour of CBC, on the grounds that the words in the broadcast were true,” according to CBC producer Lynn Burgess: Continue reading Nutrition researcher Chandra loses libel case against CBC